Skip to content

A study comparing vasopressin and norepinephrine as the first medicine to treat high lung pressure in newborn babies.

Norepinephrine versus Vasopressin in Persistent Pulmonary Hypertension of the Newborn : Randomized controlled trial - NOVA-PPHN

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097464
Enrollment
88
Registered
2025-11-14
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P293- Persistent fetal circulation

Interventions

Intervention1: Vasopressin: - Starting dose: 0.0002 IU/kg/min. - Titrated every 15 minutes by 0.0002IU/kg/min to target MAP. - Maximum dose: 0.002 IU/kg/min. - Infusion prepared in standard NICU conce

Sponsors

Bhrajishna Pallapothu
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Gestational age more than or equal to 34 weeks. 2. Echocardiographic evidence of PPHN done by a neonatologist trained in functional echo or pediatric cardiologist 3. Systemic hypotension defined as mean arterial pressure (MAP) below 3rd centile as per charts by Giesinger et al. 4. Parental/guardian written informed consent.

Exclusion criteria

Exclusion criteria: 1. Major critical congenital heart disease (except PDA or PFO). 2. Congenital diaphragmatic hernia. 3. Lethal congenital anomalies. 4. more than 1 hour prior exposure to NE or AVP.

Design outcomes

Primary

MeasureTime frame
Change in Oxygenation Index (OI) from baselineTimepoint: 12 hrs

Secondary

MeasureTime frame
Mean arterial pressureTimepoint: 1h, 6h, 12h, and 24h;Treatment failure rate (need for crossover vasopressor or addition of a second-line vasoactive agent)Timepoint: 24 hr;Vasoactive-Inotropic Score (VIS)Timepoint: 6h, 12h and 24h;Duration of invasive ventilationTimepoint: at discharge;Need for iNOTimepoint: At discharge;Time to discontinuation of iNOTimepoint: At discharge;Incidence of hyponatremia (serum Na less than 130 mmol/L)Timepoint: 72h;Incidence of clinically significant arrhythmias requiring interventionTimepoint: At discharge;Incidence of serious adverse events (SAE): NEC (after stage II), grade more than 3 IVH, or peripheral ischemia.Timepoint: At discharge;Oliguria less than 1ml/kg/hr, doubling of serum creatinineTimepoint: 72h;Lacte clearance from baselineTimepoint: 12h and 24h;All-cause mortalityTimepoint: At discharge;Composite outcome of death or need for iNOTimepoint: At discharge

Countries

India

Contacts

Public ContactBhrajishna Pallapothu

Rainbow Childrens Hospital

dr.bhrajishnap@rainbowhospitals.in9492491229

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026